Following clinical trials involving cardiovascular ischemic events in patients taking Zelnorm, Novartis has complied with an FDA request to suspend marketing of the drug, which is often prescribed for irritable bowel syndrome. We encourage any patients currently taking Zelnorm to contact their doctor to explore other treatment options. Visit www.zelnorm.com for more information.